𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

✍ Scribed by Nancy L. Geller; Cora N. Sternberg; Darryl Penenberg; Howard Scher; Alan Yagoda

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
594 KB
Volume
67
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pretreatment prognostic factors for surv
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
✍ Joaquim Bellmunt; Joan Albanell; Luis Paz-Ares; Miguel A. Climent; Jose L. GonzΓ‘ πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 74 KB

## Background: New chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplat

A phase II trial of neoadjuvant methotre
A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma
✍ Louise E. Morrell; Young J. Lee; Judith Hurley; Mayda Arias; Carolyn Mies; Steph πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 2 views

## Background: Traditionally, primary surgical therapy is considered unsuitable for the treatment of patients with locally advanced breast carcinoma (labc). multiple reports have documented the efficacy of primary chemotherapy in this group of patients. the purpose of this study was to investigate

Treatment options for muscle-invasive ur
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin : Report of Southwest Oncology Group Trial 8733
✍ Celestia S. Higano; Catherine M. Tangen; Wael A. Sakr; James Faulkner; Saul E. R πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

## Abstract ## BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates for cisplatin‐based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients. ## METHODS. Eligible patients had pr